Back to Journals » Neuropsychiatric Disease and Treatment » Volume 9

Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine

Authors Ünsal C, Albayrak Y, Albayrak N, Kuloğlu M, Hashimoto K

Received 3 August 2013

Accepted for publication 11 September 2013

Published 11 October 2013 Volume 2013:9 Pages 1545—1552

DOI https://doi.org/10.2147/NDT.S52463

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Cüneyt Ünsal,1 Yakup Albayrak,1 Neslihan Albayrak,2 Murat Kuloğlu,3 Kenji Hashimoto4

1Department of Psychiatry, Namik Kemal University School of Medicine, Tekirdag, Turkey; 2Department of Cardiology, Kirklareli State Hospital, Kirklareli, Turkey; 3Department of Psychiatry, Akdeniz University School of Medicine, Antalya, Turkey; 4Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan

Background: Second generation antipsychotics (SGAs) are currently the most prescribed drugs in the treatment of schizophrenia. Despite their advantages, which include greater improvement in negative symptoms, cognitive function, prevention of deterioration, quality of life, and fewer extrapyramidal symptoms, the concern regarding metabolic abnormalities which might cause cardiovascular diseases during treatment with SGAs have been rising. Paraoxonase 1 (PON1) is an enzyme mostly located on high-density lipoprotein particles, and has been shown to protect or inhibit lipoprotein oxidation. Growing evidence suggests that PON1 plays a key role in the pathophysiology of atherosclerosis.
Methods: In the present study, we measured serum PON1 activity and serum levels of total cholesterol (TC), triglyceride, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) in patients with schizophrenia, who had been treated with either olanzapine or quetiapine, and in healthy controls. Thirty five patients who had been treated with olanzapine, 29 patients who had been treated with quetiapine, and 32 age, sex, and smoking status-matched healthy control (HC) participants were enrolled. Serum PON1 activity and serum levels of TC, triglyceride, HDL-C, and LDL-C were measured.
Results: Serum PON1 activity in the olanzapine group was significantly lower than that of HC and quetiapine groups. Furthermore, serum levels of TC and LDL-C in the olanzapine group were significantly higher than those of quetiapine and HC groups. Interestingly, there was a positive correlation between PON1 activity and HDL-C levels in the olanzapine group.
Conclusion: These findings suggest that serum PON1 activity in patients treated with olanzapine was lower than that of HC and quetiapine groups, and that PON1 may play a role in the metabolic side effects associated with olanzapine treatment. A further study to examine the relationship between serum PON1 activity and cardiovascular and metabolic side effects during treatment with SGAs will be of great interest.

Keywords: second generation antipsychotics, SGA, atherosclerosis, metabolic, dyslipidemia, LDL-C

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Increased serum levels of apoptosis in deficit syndrome schizophrenia patients: a preliminary study

Beyazyüz M, Küfeciler T, Bulut L, Ünsal C, Albayrak Y, Akyol ES, Baykal S, Kuloglu M, Hashimoto K

Neuropsychiatric Disease and Treatment 2016, 12:1261-1268

Published Date: 23 May 2016

Neurological soft signs might be endophenotype candidates for patients with deficit syndrome schizophrenia

Albayarak Y, Akyol ES, Beyazyüz M, Baykal S, Kuloglu M

Neuropsychiatric Disease and Treatment 2015, 11:2825-2831

Published Date: 29 October 2015

Decreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndrome

Akyol ES, Albayrak Y, Beyazyüz M, Aksoy N, Kuloglu M, Hashimoto K

Neuropsychiatric Disease and Treatment 2015, 11:865-872

Published Date: 30 March 2015

Increased serum dehydroepiandrosterone sulfate in the first episode but not in subsequent episodes in male patients with schizophrenia

Beyazyüz M, Albayrak Y, Beyazyüz E, Ünsal C, Göka E

Neuropsychiatric Disease and Treatment 2014, 10:687-693

Published Date: 29 April 2014

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010